This phase I trial is evaluating a new targeted cancer drug in patients with Non-Hodgkin's Lymphoma who have gotten worse or not responded to prior treatment.
This trial is treating patients with B-Cell Non-Hodgkin's Lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
An Open-Label, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of RO7227166 (a CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This trial has three parts, to which eligible patients will be assigned: dose escalation (Parts 1 and 2) and dose expansion (Part 3). Eligible patients will receive intravenous RO7227166 in combination with obinutuzumab and glofitamab. A fixed dose of obinutuzumab will be administered seven days prior to the first administration of RO7227166 and seven days prior to the first administration of glofitamab.
Recruiting Hospitals Read More